

LISTING OF THE CLAIMS

This listing of claims replaces all prior versions and listings of the claims.

Claims 1-5. (Cancelled)

6. (Previously Presented) A formulation for the treatment, repair or prevention of, or the modulation of inflammation associated with damage to connective tissue comprising:

one or more avocado/soybean unsaponifiables together with an aminosugar or a glycosaminoglycan component.

7. (Previously Presented) A formulation for the treatment, repair or prevention of, or the modulation of inflammation associated with damage to connective tissue comprising:

one or more avocado/soybean unsaponifiables;
an aminosugar; and
a glycosaminoglycan component.

8. (Previously Presented) The formulation of claims 6 or 7, wherein the aminosugar is natural, synthetic or semi-synthetic.

9. (Previously Presented) The formulation of claims 6 or 7, wherein the one or more avocado/soybean unsaponifiables is natural, synthetic or semi-synthetic.

10. (Previously Presented) The formulation of claims 6 or 7, wherein the aminosugar has been chemically modified by one or more of esterification, sulfation, polysulfation, acetylation and methylation.

11. (Previously Presented) The formulation of claims 6 or 7, wherein the aminosugar is selected from the group consisting of glucosamine, glucosamine salts, and mixtures thereof.

12. (Previously Presented) The formulation of claims 6 or 7, wherein the aminosugar is selected from the group consisting of glucosamine hydrochloride, glucosamine sulfate, glucosamine phosphate, mannosamine and salts of N-acetylglucosamine.

13. (Previously Presented) The formulation of claims 6 or 7, wherein the glycosaminoglycan component comprises a natural, synthetic or semi-synthetic glycosaminoglycan, a glycosaminoglycan-like compound, a glycosaminoglycan precursor or fragments of a glycosaminoglycan.

14. (Previously Presented) The formulation of claims 6 or 7, wherein the glycosaminoglycan component has been chemically modified by one or more of esterification, sulfation, polysulfation, acetylation and methylation.

15. (Previously Presented) The formulation of claims 6 or 7, wherein the glycosaminoglycan component is selected from the group consisting of chondroitin, chondroitin salts, hyaluronic acid, pentosan polysulfate and mixtures thereof.

16. (Previously Presented) The formulation of claims 6 or 7, wherein the glycosaminoglycan component is chondroitin sulfate.

17. (Previously Presented) The formulation of claims 6 or 7, wherein a dose of the one or more avocado/soybean unsaponifiables ranges from about 5 milligrams to about 5 grams.

18. (Previously Presented) The formulation of claims 6 or 7, wherein a dose for a small animal of the one or more avocado/soybean unsaponifiables ranges from about 5 milligrams to about 1000 milligrams.

19. (Previously Presented) The formulation of claims 6 or 7, wherein a dose for a human of the one or more avocado/soybean unsaponifiables ranges from about 50 milligrams to about 1500 milligrams.

20. (Previously Presented) The formulation of claim 6 or 7, wherein a dose for a large animal of the one or more avocado/soybean unsaponifiables ranges from about 100 milligrams to about 5 grams.

21. (Previously Presented) The formulation of claims 6 or 7, wherein a dose of the aminosugar ranges from about 25 milligrams to about 12 grams.

22. (Previously Presented) The formulation of claims 6 or 7, wherein a dose for a small animal of the aminosugar ranges from about 25 milligrams to about 3 grams.

23. (Previously Presented) The formulation of claims 6 or 7, wherein a dose for a human of the aminosugar ranges from about 100 milligrams to about 4 grams.

24. (Previously Presented) The formulation of claims 6 or 7, wherein a dose for a large animal of the aminosugar ranges from about 300 milligrams to about 12 grams.

25. (Previously Presented) The formulation of claims 6 or 7, wherein a dose of the glycosaminoglycan component ranges from about 15 milligrams to about 12 grams.

26. (Previously Presented) The formulation of claims 6 or 7, wherein a dose for a small animal of the glycosaminoglycan component ranges from about 15 milligrams to about 2 grams.

27. (Previously Presented) The formulation of claims 6 or 7, wherein a dose for a human of the glycosaminoglycan component ranges from about 75 milligrams to about 4 grams.

28. (Previously Presented) The formulation of claims 6 or 7, wherein a dose for a large animal of the glycosaminoglycan component ranges from about 300 milligrams to about 12 grams.

29. (Previously Presented) A formulation for the treatment, repair or prevention of, or the modulation of inflammation associated with damage to connective tissue comprising:

one or more avocado/soybean unsaponifiables together with one or more of a component selected from the group consisting of an aminosugar, a glycosaminoglycan component, S-adenosylmethionine (SAME), superoxide dismutase (SOD), L-ergothionine, diacerein and collagen type II.

30. (Previously Presented) The formulation of any one of claims 6, 7 or 29, wherein the formulation is prepared for intramuscular, intravenous, oral, subcutaneous, rectal, topical, transcutaneous, intranasal, intraarticular, sublingual and intraperitoneal administration.

31. (Previously Presented) A method of preventing, treating, repairing or modulating inflammation associated with damage to connective tissue in humans and animals comprising administering the formulation of any one of claims 6, 7 or 29 to a human or animal in need thereof.

32. (Previously Presented) The method of claim 31, wherein the formulation is administered intramuscularly, intravenously, orally, subcutaneously, rectally, topically, transcutaneously, intranasally, intraarticularly, sublingually and intraperitoneally.

33. (Previously Presented) A formulation for the treatment, repair or prevention of, or the modulation of inflammation associated with damage to connective tissue comprising:

one or more avocado/soybean unsaponifiables together with one or more of an aminosugar and/or a glycosaminoglycan.

34. (Previously Presented) The formulation of claim 33, wherein the aminosugar is natural, synthetic or semi-synthetic.

35. (Previously Presented) The formulation of claim 33, wherein the aminosugar is selected from the group consisting of glucosamine, glucosamine salts, and mixtures thereof.

36. (Previously Presented) The formulation of claim 33, wherein the one or more avocado/soybean unsaponifiables is natural, synthetic or semi-synthetic.

37. (Previously Presented) The formulation of claim 33, wherein the glycosaminoglycan is natural, synthetic or semi-synthetic.

38. (Previously Presented) The formulation of claim 33, wherein the glycosaminoglycan is selected from the group consisting of hyaluronic acid, chondroitin sulfate, chondroitin sulfate salts, and mixtures thereof.

39. (Previously Presented) The formulation of claim 33, wherein a dose of the one or more avocado/soybean unsaponifiables ranges from about 5 milligrams to about 5 grams.

40. (Previously Presented) The formulation of claim 33, wherein a dose of the

aminosugar ranges from about 25 milligrams to about 12 grams.

41. (Previously Presented) The formulation of claim 33 wherein a dose of the glycosaminoglycan ranges from about 15 milligrams to about 12 grams.

42. (Previously Presented) A method of preventing, treating, repairing or modulating inflammation associated with damage to connective tissue in humans and animals comprising administering the formulation of claim 33 to a human or animal in need thereof.

43. (Previously Presented) A formulation for the treatment, repair or prevention of, or the modulation of inflammation associated with damage to connective tissue comprising:

one or more avocado/soybean unsaponifiables together with one or more of an aminosugar and/or fragments of a glycosaminoglycan.

44. (Previously Presented) The formulation of claim 43 wherein the aminosugar is natural, synthetic or semi-synthetic.

45. (Previously Presented) The formulation of claim 43, wherein the aminosugar is selected from the group consisting of glucosamine, glucosamine salts, and mixtures thereof.

46. (Previously Presented) The formulation of claim 43, wherein the one or more avocado/soybean unsaponifiables is natural, synthetic or semi-synthetic.

47. (Previously Presented) The formulation of claim 43, wherein the fragments of the glycosaminoglycan are natural, synthetic or semi-synthetic.

48. (Previously Presented) The formulation of claim 43, wherein the fragments of the glycosaminoglycan are selected from the group consisting of fragments of chondroitin, fragments of chondroitin sulfate, fragments of chondroitin salts, and mixtures thereof.

49. (Previously Presented) The formulation of claim 43, wherein a dose of the one or more avocado/soybean unsaponifiables ranges from about 5 milligrams to about 5 grams.

50. (Previously Presented) The formulation of claim 43, wherein a dose of the

aminosugar ranges from about 25 milligrams to about 12 grams.

51. (Previously Presented) The formulation of claim 43, wherein a dose of the fragments of the glycosaminoglycan ranges from about 15 milligrams to about 12 grams.

52. (Previously Presented) A method of preventing, treating, repairing, or modulating inflammation associated with damage to connective tissue in humans and animals comprising administering the formulation of claim 43 to a human or animal in need thereof.

53. (Previously Presented) A formulation for the treatment, repair or prevention of, or the modulation of inflammation associated with damage to connective tissue comprising:
one or more avocado/soybean unsaponifiables together with one or more of an aminosugar and/or a glycosaminoglycan-like compound.

54. (Previously Presented). The formulation of claim 53, wherein the aminosugar is natural, synthetic or semi-synthetic.

55. (Previously Presented) The formulation of claim 53, wherein the aminosugar is selected from the group consisting of glucosamine, glucosamine salts, and mixtures thereof.

56. (Previously Presented) The formulation of claim 53, wherein the one or more avocado/soybean unsaponifiables is natural, synthetic or semi-synthetic.

57. (Previously Presented) The formulation of claim 53, wherein the glycosaminoglycan-like compound is natural, synthetic or semi-synthetic.

58. (Previously Presented) The formulation of claims 53, wherein the glycosaminoglycan-like compound is selected from the group consisting of pentosan polysulfate, pentosan polysulfate salts, and mixtures thereof.

59. (Previously Presented) The formulation of claims 53, wherein a dose of the one or more avocado/soybean unsaponifiables ranges from about 5 milligrams to about 5 grams.

60. (Previously Presented) The formulation of claims 53, wherein a dose of the

aminosugar ranges from about 25 milligrams to about 12 grams.

61. (Previously Presented) The formulation of claims 53, wherein a dose of the glycosaminoglycan-like compound ranges from about 15 milligrams to about 12 grams.

62. (Previously Presented) A method of preventing, treating, repairing or modulating inflammation associated with damage to connective tissue in humans and animals comprising administering the formulation of claims 53 to a human or animal in need thereof.